.jpg)
News & Events
February 17. 2021
FibroGenesis induces cancer regression using fibroblasts
​
December 10, 2020
FibroGenesis Uses Apple Watch to Extend Its Clinical Monitoring of COVID-19 Patients
​
November 10, 2020
FibroGenesis Reaches Milestone to File Its 250th Patent
​
October 1, 2020
FibroGenesis Announces Collaboration Agreement with Brazilian Biotech R4D Read More
September 28, 2020
FibroGenesis Announces Manufacturing Agreement Read More
August 12, 2020
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Read More
July 21, 2020
FibroGenesis Reduces COVID-19 Lung Scarring in Animal Model Read More
July 1, 2020
FibroGenesis Identifies Mechanism Responsible for Blocking COVID-19 Lung Inflammation Read More
​
May 21, 2020
FibroGenesis Announces COVID-19 Breakthrough Read More
​
April 21, 2020
FibroGenesis Files Its Landmark 200th Patent Read More
April 1, 2020
FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS Read More
March 10, 2020
FibroGenesis Files Patent to Treat Coronavirus (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Read More
February 3, 2020
FibroGenesis to Present at LSX World Congress Read More
January 28, 2020
SpinalCyte Changes Name To FibroGenesis Read More
​
December 12, 2019
SpinalCyte CEO, Pete O'Heeron named to 30 Best CEO of 2020 List
December 11, 2019
SpinalCyte Announces New Australian Patent Read More
October 23, 2019
CEO/CFO Magazine Interviews SpinalCyte CEO, Pete O'Heeron Read More
October 21, 2019
SpinalCyte to Present at BIO Investor Forum Read More
October 15, 2019
SpinalCyte Announces New Japanese Patent Read More
September 19, 2019
SpinalCyte Announces New International Patent Read More
​
June 5, 2019
SpinalCyte to Present at Boao Forum in Qingdao, China Read More
May 15, 2019
SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology Read More
​
March 28, 2019
SpinalCyte to Provide Clinical Trial Update at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting Read More
March 18, 2019
SpinalCyte to Present at China Focus @ Europe Vienna, Austria Read More
March 11, 2019
SpinalCyte Announces Two New Patents Read More
February 4, 2019
SpinalCyte to Present at the 2019 BIO CEO & Investor Conference Read More
January 8, 2019
SpinalCyte Announces New International Patent Read More
​
November 28, 2018
SpinalCyte Press Release FDA IND Acceptance Read More
November 14, 2018
SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection Read More
November 7, 2018
SpinalCyte Announces EU and Hong Kong Patents Read More
October 25, 2018
SpinalCyte Announces Sustained Improvement in Pain Scores at 12-Month Endpoint Read More
October 11, 2018
SpinalCyte Announces 4th Peer Reviewed Publication On CybroCell Technology Read More
August 28, 2018
SpinalCyte, LLC Announces New U.S. Patent Read More
July 31, 2018
SpinalCyte Announces Publication of Fibroblast Study in Journal of Translational Medicine Read More
May 17, 2018
SpinalCyte Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018 Read More
April 12, 2018
SpinalCyte Applies with FDA to Expand Human Clinical Trial of CybroCell™ Dermal Fibroblasts as Investigational New Drug (IND) Read More
April 3, 2018
SpinalCyte Announces Positive MRI Results For Phase 1/Phase 2 Landmark Human Trial Read More
February 13, 2018
SpinalCyte Announces Landmark Human Trial and Suggests Treatment Could Eliminate Need for Opioids in Some Patients Read More
​
December 27, 2017
SpinalCyte, LLC Announces 25th Patent Read More
​
September 20, 2017
SpinalCyte Announces New Australian Patent Read More
​
July 20, 2017
SpinalCyte Announces New Japanese Patent Read More
​
April 27, 2017
SpinalCyte, LLC Receives New Australian Patent Read More
​
April 6, 2017
SpinalCyte, LLC Receives New European Patent Read More
​
March 14, 2017
First Fibroblast Injection Performed in SpinalCyte’s Landmark Trial for Spinal Disc Regeneration Read More
​
February 9, 2017
SpinalCyte Receives New U.S. Patent Read More
​
January 25, 2017
SpinalCyte Enrolls First Patient in Phase I Clinical Trial Read More
​
January 6, 2017
SpinalCyte, LLC Receives New U.S. Patent Read More
​
December 13, 2016
SpinalCyte, LLC Receives Institutional Review Board Approval for Phase I Clinical Trial
​
May 4, 2016
SpinalCyte Receives New U.S. Patent for Biodegradable and Resorbable Structure
​
April 22, 2016
SpinalCyte, LLC Receives New Canadian Patent for Spinal Disc Tissue Engineering
​
April 19, 2016
SpinalCyte Announces Landmark Scientific Breakthrough From Phase II Animal Trials
​
April 15, 2016
SpinalCyte, LLC Announces Publication in Global Spine Journal
​
March 29, 2016
SpinalCyte, LLC Announces New Results from Phase II Animal Trials of Cell Therapy to Regenerate the Spinal Disc
​
January 8, 2016
SpinalCyte, LLC Receives New Chinese Patent for Spinal Disc Tissue Engineering
​
October 25, 2015
SpinalCyte, LLC Presents at MENA Private Equity & Venture Capital Summit
​
October 14, 2015
SpinalCyte, LLC Receives New Australian Patent for Spinal Disc Tissue Engineering
​
September 22, 2015
SpinalCyte Receives New U.S. Patent for Tissue Engineering
​
June 16, 2014
SpinalCyte, LLC Announces Final Animal Trials for Spinal Disc Tissue Engineering
​
May 20, 2014
SpinalCyte Receives U.S. Patent